Metastatic breast cancer - Overview of treatment

被引：34

作者：

Ali, SM

Harvey, HA

Lipton, A

机构：

[1] MS Hershey Med Ctr, Hershey, PA USA

[2] VA Med Ctr, Lebanon, PA 17042 USA

来源：

CLINICAL ORTHOPAEDICS AND RELATED RESEARCH | 2003年 / 415期

关键词：

D O I：

10.1097/01.blo.0000092981.12414.7b

中图分类号：

R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];

学科分类号：

摘要：

Patients with metastatic breast cancer have a median survival of 2 to 3 years. Twenty percent of the patients who present with bone-only metastasis will be alive at 5 years from diagnosis. Current therapies are aimed at improving the quality of life, symptom control, and prolongation of survival. Newer endocrine and chemotherapeutic drugs are available to the medical oncologist for care of patients with metastatic breast cancer. We will briefly review the new advances in the treatment of metastatic breast cancer.

引用

收藏

页码：S132 / S137

页数：6

相关论文

共 23 条

[1]

Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients [J].

Alexandre, J ;

Bleuzen, P ;

Bonneterre, J ;

Sutherland, W ;

Misset, JL ;

Guastalla, JP ;

Viens, P ;

Faivre, S ;

Chahine, A ;

Spielman, M ;

Bensmaïne, A ;

Marty, M ;

Mahjoubi, M ;

Cvitkovic, E .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :562-573

[2]

Ali SM, 2002, CLIN CHEM, V48, P1314

[3]

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate [J].

Buzdar, A ;

Douma, J ;

Davidson, N ;

Elledge, R ;

Morgan, M ;

Smith, R ;

Porter, L ;

Nabholtz, J ;

Xiang, X ;

Brady, C .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3357-3366

[4]

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials [J].

Buzdar, A ;

Jonat, W ;

Howell, A ;

Jones, SE ;

Blomqvist, C ;

Vogel, CL ;

Eiermann, W ;

Wolter, JM ;

Azab, M ;

Webster, A ;

Plourde, PV .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) :2000-2011

[5]

Clarke M, 1998, LANCET, V351, P1451

[6]

THE CLINICAL COURSE OF BONE METASTASES FROM BREAST-CANCER [J].

COLEMAN, RE ;

RUBENS, RD .

BRITISH JOURNAL OF CANCER, 1987, 55 (01) :61-66

[7]

Efficacy of zoledronic acid and pamidronate in breast cancer patients: A comparative analysis of Randomized phase III trials [J].

Coleman, RE .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (06) :S25-S31

[8]

Clinical course and prognostic factors following bone recurrence from breast cancer [J].

Coleman, RE ;

Smith, P ;

Rubens, RD .

BRITISH JOURNAL OF CANCER, 1998, 77 (02) :336-340

[9]

Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: Results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group [J].

Del Mastro, L ;

Venturini, M ;

Lionetto, R ;

Carnino, F ;

Guarneri, D ;

Gallo, L ;

Contu, A ;

Pronzato, P ;

Vesentini, L ;

Bergaglio, M ;

Comis, S ;

Rosso, R .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2213-2221

[10]

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate [J].

Hortobagyi, GN ;

Theriault, RL ;

Lipton, A ;

Porter, L ;

Blayney, D ;

Sinoff, C ;

Wheeler, H ;

Simeone, JF ;

Seaman, JJ ;

Knight, RD ;

Heffernan, M ;

Mellars, K ;

Reitsma, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) :2038-2044